School reopening was associated with a 1.2 percentage-point drop in monthly prevalence of mental health diagnoses
FRIDAY, Dec. 12, 2025 (HealthDay News) — In-person learning appears to be important for children”s mental health, according to a study published online Dec. 8 in Epidemiology.
Pelin Ozluk, Ph.D., from Elevance Health, Inc., in Indianapolis, and colleagues examined the impacts of pandemic-era school reopenings on children”s mental health and health care expenditures in a difference-in-differences analysis across 24 California counties. Data were obtained from medical claims for 185,735 participants.
The researchers found a 1.2 percentage-point drop in monthly prevalence of mental health diagnoses in association with school reopening and a 10.6 percent decrease in related health care spending. Anxiety and depression were the mental health conditions that saw the largest differential between in-person and remote school districts. Among girls, the effects were strongest.
“As we consider future public health emergencies, this study suggests we need to prioritize safe school reopenings and ensure children have access to the social and emotional resources that schools provide,” senior author Rita Hamad, M.D., Ph.D., from the Harvard School of Public Health in Boston, said in a statement. “Policies should focus not only on infection control, but also on the mental well-being of children, recognizing that schools are a critical part of their support system.”
Abstract/Full Text (subscription or payment may be required)
Maternal Night-Shift Work Tied to Later Neurodevelopmental Issues in Offspring
Low Levels of Placental Growth Factor in Pregnancy Linked to Subsequent ADHD in Offspring
Better Youth Fitness May Lower Risk for Depression in Adulthood
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
More Than 1 in 4 Americans Misrepresent Symptoms to Get Antibiotics
Hospital Outcomes Better When Patients Treated by Female Physicians
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers